Litcius/Paper detail

The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate

Hao Wang, Rongjuan Pei, Xin Li, Weilong Deng, Shuai Xing, Yanan Zhang, Chen Zhang, Shuai He, Hao Sun, Shuqi Xiao, Jin Xiong, Yecheng Zhang, Xinwen Chen, Yaxin Wang, Yu Guo, Bo Zhang, Luqing Shang

2022European Journal of Medicinal Chemistry26 citationsDOIOpen Access PDF

Topics & Concepts

PeptidomimeticProteaseChemistryCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Protease inhibitor (pharmacology)Structure–activity relationshipVirologyDrug discoveryDrug repositioningLigand (biochemistry)IC50Coronavirus disease 2019 (COVID-19)DrugEnzymePharmacologyVirusBiochemistryIn vitroBiologyInfectious disease (medical specialty)MedicineViral loadReceptorDiseasePeptidePathologyAntiretroviral therapySARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery Methodsvaccines and immunoinformatics approaches
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate | Litcius